(IYH) U.S. Healthcare - Overview
Etf: Pharmaceutical, Biotech, Medical Devices, Health Services
Dividends
| Dividend Yield | 1.29% |
| Yield on Cost 5y | 1.61% |
| Yield CAGR 5y | -27.64% |
| Payout Consistency | 95.3% |
| Payout Ratio | - |
| Risk 5d forecast | |
|---|---|
| Volatility | 15.6% |
| Relative Tail Risk | -0.34% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.25 |
| Alpha | -3.94 |
| Character TTM | |
|---|---|
| Beta | 0.531 |
| Beta Downside | 0.529 |
| Drawdowns 3y | |
|---|---|
| Max DD | 17.91% |
| CAGR/Max DD | 0.40 |
Description: IYH U.S. Healthcare January 12, 2026
The iShares U.S. Healthcare ETF (IYH) is designed to track an index that reflects the performance of the U.S. healthcare equity sector. By policy, the fund must allocate at least 80 % of its assets to the securities that compose that index, and it is classified as a non-diversified ETF, meaning a relatively high concentration in a limited number of holdings.
Key metrics to watch: the fund’s expense ratio is 0.42 % (annual), and its top ten holdings-dominated by large-cap pharma and medical-device firms such as Johnson & Johnson, UnitedHealth Group, and Pfizer-account for roughly 45 % of assets, underscoring the non-diversified nature. Recent sector drivers include rising Medicare-advantage enrollment, robust biotech R&D pipelines, and the aging U.S. population, which together have supported a year-to-date return of about 8 % (as of Q4 2025). However, the ETF’s performance is highly sensitive to regulatory changes and drug-approval cycles, so investors should monitor FDA policy shifts and prescription-drug pricing legislation.
For a deeper, data-driven dive into IYH’s risk-adjusted outlook, you might explore the analytics on ValueRay.
What is the price of IYH shares?
Over the past week, the price has changed by +0.90%, over one month by -1.16%, over three months by +6.68% and over the past year by +8.06%.
Is IYH a buy, sell or hold?
What are the forecasts/targets for the IYH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 69.9 | 6.2% |
IYH Fundamental Data Overview February 04, 2026
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 3.62b USD (3.62b + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 3.62b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 3.62b / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 7.87% (E(3.62b)/V(3.62b) * Re(7.87%) + (debt-free company))
Discount Rate = 7.87% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Fair Price DCF = unknown (Cash Flow 0.0)